By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cubist
Pharmaceuticals Inc. v. Hospira Inc.
1:12-cv-01142;
filed September 17, 2012 in the District Court of Delaware

Infringement
of U.S. Patent Nos. 6,468,967 ("Methods for Administration of Antibiotics,"
issued October 22, 2002), 6,852,689 (same title, issued February 8, 2005),
RE39,071 ("Anhydro-and Isomer-A-21978C Cyclic Peptides," April 18,
2006), 8,058,238 ("High Purity Lipopeptides," issued November 15,
2011), and 8,129,342 (same title, issued March 6, 2012) following a Paragraph
IV certification as part of Hospira's filing of an ANDA to manufacture a
generic version of Cubist's Cubicin® (daptomycin for injection, used for the
treatment of skin infections caused by certain Gram-positive
microorganisms).  View the complaint here.

Otsuka
Pharmaceutical Co., Ltd. v. Silarx Pharmaceuticals, Inc.
3:12-cv-05809;
filed September 14, 2012 in the District Court of New Jersey

Infringement
of U.S. Patent Nos. 6,977,257 ("Aripiprazole Oral Solution," issued
December 20, 2005) and 5,006,528 ("Carbostyril Derivatives," issued
April 9, 1991) following a Paragraph IV certification as part of Silarx's
filing of an ANDA to manufacture a generic version of Otsuka's Abilify®
(aripiprazole, used to treat bipolar disorder and schizophrenia).  View the complaint here.